Page 1

Atossa THERAPEUTICS Advancing ( Z ) -Endoxifen A potential best - in - class oral SERM / SERD for estrogen - driven diseases Corporate & Investor Presentation September 2026 NASDAQ : ATOS www.atossatherapeutics.com Seattle , Washington